Viral infections, particularly enteroviruses, 1 have been hypothesized to cause type 1 diabetes (T1D). 2 Recent studies suggest that respiratory tract infections are associated with increased T1D risk if they are encountered within the first 6 months. 3 We explored associations between infection types during the first 2 years and between respiratory tract infections in the first 6 months and T1D in a population-based cohort.
Results | Of the 295 420 infants included (male, 55.0%), 720 were diagnosed with T1D over a median follow-up of 8.5 years (interquartile range, 7.5-9.3), for an incidence of 29 diagnoses per 100 000 children annually. At least 1 infection was reported during the first 2 years of life in 92.9% of all children, and in 96.7% of children with T1D (χ 2 P < .001). Most children experienced respiratory (87.1%) and viral (83.5%) infections.
Respiratory tract infections between birth and 2.9 months of age or between 3 and 5.9 months occurred in 278 children who developed T1D (38.6%) and 100 693 children who did not develop T1D (34.2%). T1D risk was increased in children who had a respiratory tract infection compared with children who had no respiratory tract infections in these age intervals (HR, 1.17 [95% CI, 1.00-1.37]) ( Figure 1 ). Viral infections occurred between birth and 5.9 months of age in 243 children who developed T1D (33.8%) and 86 758 children who did not develop T1D (29.4%). An increased T1D risk was observed compared with children without viral infections (HR, 1.19 [95% CI, 1.01-1.39]).
Respiratory tract infections occurring in both age intervals (birth to 2.9 months and 3 to 5.9 months) were reported for 56 children with T1D (7.8%). Having respiratory tract infections in both age intervals was associated with an increased T1D risk compared with having infections in only 1 age interval or having no infections (cumulative 5-year risk per 100 000: 206 for infections in both intervals, 142 for infection in 1 age interval, 118 for no infections, P = .01). Risk was particularly increased if the infections were caused by viruses (cumulative 5-year risk per 100 000: 270 for infections in both age intervals, 145 for infection in 1 age interval, 120 for no infections; P < .001, Figure 2 ). No association was found between respiratory tract infections in the first 6 months and JIA (cumulative 5-year risk per 100 000: 102 for infections in both age intervals, 99 for infection in 1 age interval, 89 for no infections; P = .78).
Discussion | Recurrent viral respiratory tract infections during the first 6 months were associated with T1D development by age 8 years in a large, population-based sample. It is unknown whether the association with early infections reflects increased exposure to virus or an impairment of the immune system response, perhaps due to genetic susceptibility. A similar study from Taiwan found that enterovirus infections were associated with increased T1D risk but was unable to investigate different time windows for infection exposure. 5 We were unable to adjust for potential confounding factors such as family history of T1D or delivery mode as these data were unavailable. We did not have data on specific viral infections. Furthermore, we investigated several infection types with different exposure ages, potentially introducing multiple testing errors. However, the association of respiratory tract infections in the first 6 months with T1D is consistent with smaller studies assessing autoantibody development, 3, 6 suggesting that the first half-year of life is crucial for the development of the immune system and autoimmunity. 
COMMENT & RESPONSE

Noninvasive Ventilation and Outcomes Among Immunocompromised Patients
To the Editor The use of noninvasive ventilation as first-line therapy for immunocompromised patients with acute respiratory failure remains controversial. 1,2 Dr Lemiale and colleagues 3 reported the largest randomized clinical trial to date (374 immunocompromised patients) with the aim of assessing whether noninvasive ventilation could improve outcomes. No difference was found between patients treated with oxygen therapy alone or with noninvasive ventilation. However, nearly 40% of patients in both groups received high-flow oxygen through nasal cannula. The reason for using high-flow oxygen in place of standard oxygen could be either more severe respiratory disease or changes in clinical practice in the participating centers leading to routine use of high-flow oxygen as standard therapy. A recent randomized clinical trial including 310 patients admitted to the intensive care unit for acute respiratory failure found a lower mortality rate when patients were treated with high-flow oxygen alone compared with standard oxygen or noninvasive ventilation. 4 The beneficial effects of high-flow oxygen were even more pronounced in the patients with severe hypoxemia, with a significantly reduced intubation rate. In the present study, high-flow oxygen may have masked the potential beneficial or deleterious effects of noninvasive ventilation or oxygen therapy alone.
Furthermore, the relatively low severity of respiratory distress of the patients included in the study might attenuate the importance of the findings. Nearly half had a respiratory rate below 25/min at randomization, contrasting with a low ratio of PaO 2 to fraction of inspired oxygen (FIO 2 ). 3 This contrast raises a question about the accuracy of the PaO 2 :FIO 2 ratio estimated during spontaneous breathing. The calculation of the ratio was not described in the article and could have overestimated respiratory severity. The authors performed a post hoc subgroup analysis based on the delivered oxygen flow rate at inclusion (≤9 L/min vs >9 L/min) that did not show any difference in mortality between patients treated with noninvasive ventilation or oxygen alone. A subgroup analysis by respiratory rate might have been more discriminating.
The results of the study by Lemiale et al stand in contrast to recent findings suggesting that the use of high-flow oxygen with noninvasive ventilation could be the best strategy for immunocompromised patients. 5 The increasing use of high-flow oxygen among patients with acute respiratory failure raises questions about the most effective treatment and about what control group should be used in future Viral respiratory tract infections T1D, log-rank P <.001 T1D, log-rank P = .01 JIA, log-rank P = .97 JIA, log-rank P = .78
Infection in both age intervals (birth-2.9 mo and 3-5.9 mo) Infection in 1 age interval No infection Infection in both age intervals (birth-2.9 mo and 3-5.9 mo) Infection in 1 age interval No infection T1D indicates type 1 diabetes; JIA, juvenile idiopathic arthritis. a Diagnoses of infection, T1D and JIA (as a control autoimmune disease) were obtained using International Classification of Diseases, Tenth Revision, codes recorded in 3-month age intervals over 2 years. 
